.

  FOR IMMEDIATE RELEASE
Contact:  

Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.
215-283-6850

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]


INKINE ANNOUNCES POSITIVE CLINICAL TRIAL RESULTS:  LOW DOSE VISICOL® IS HIGHLY EFFECTIVE IN TREATMENT OF
CHRONIC CONSTIPATION
 

BLUE BELL, PA April 19, 2004 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced the successful completion of a Phase IV study of Visicol® tablets in patients with functional constipation or constipation predominant Irritable Bowel Syndrome.  The study demonstrated nearly 100% effectiveness in increasing the number of bowel movements per week while significantly reducing the associated symptoms of constipation.

 “The results of this study are consistent with what some physicians have already observed in clinical practice,” said Seymour Katz, M.D., FACP, MACG, Clinical Professor of Medicine, New York University School of Medicine, who is a study investigator at Long Island Clinical Research Associates, in Great Neck, NY.  “The success rate and rapid response of constipated patients to Visicol® are very encouraging and support further study,” added Dr. Katz. 

 The multicenter study included 40 evaluable patients with chronic constipation, which was defined as three or less bowel movements per week.  The patients were randomized to receive daily either a single four tablet dose or an eight tablet regimen, with four tablets dosed twice over 15 minutes.  Eight ounces of fluid was given with each dose and the dose could be adjusted based on response at pre-determined time intervals.  The treatment period was four weeks with weekly assessments.

 The results of the study are as follows:

 Four Tablet Dose:
The median time to first bowel movement in the four tablet group was 21 hours and by the end of week one the four tablet group averaged seven bowel movements per week.  By the end of week four, the four tablet group averaged nine bowel movements per week.  These changes were highly statistically significant.  All patients responded to therapy (by meeting defined criteria regarding an increase in the number of bowel movements) during their last week of treatment, with 88% responding in the first week.  Additionally, there was a highly statistically significant improvement in constipation-associated symptoms such as straining, cramping, bloating, rectal irritation and stool consistency when compared to baseline.  In the four-tablet group there were no withdrawals due to adverse events and there were no statistically significant changes in mean blood electrolyte levels after four weeks of therapy.

 Eight Tablet Dose:
The median time to first bowel movement in the eight-tablet group was four hours and by the end of week one the eight tablet group averaged ten bowel movements per week.  By the end of week four, the eight tablet group averaged nine bowel movements per week.  While these changes from baseline were highly statistically significant, the average change in bowel movements per week were not statistically different between the two treatment arms at any time following the end of the first treatment week.  Ninety-two percent of patients responded to therapy (by meeting defined criteria regarding an increase in the number of bowel movements) during their last week of treatment, with 88% responding in the first week.  There were statistically significant improvements in constipation-associated symptoms such as straining, cramping, bloating, and stool consistency when compared to baseline.  Four patients withdrew from the study because of non-serious adverse events.  There was a modest, but statistically significant, decrease in serum potassium at the end of the study compared to baseline consistent with the substantial increase in the number of bowel movements in the eight tablet group. 

 Seven of the patients in the study suffered from constipation predominant Irritable Bowel Syndrome, a particularly difficult type of chronic constipation to treat.  All seven patients, four of whom were in the four tablet group, responded successfully to Visicol® therapy.

 "These outstanding results show that the lowest dose of Visicol® studied was well tolerated and produced a rapid and sustained laxative effect in patients with chronic constipation.  Straining, cramping, bloating, rectal irritation, and stool consistency were greatly improved in these chronically constipated patients.  The results in patients suffering from constipation predominant Irritable Bowel Syndrome were particularly promising,” said Martin Rose, M.D., J.D., InKine's Executive Vice President for Research and Development.  "Based on these results, we intend to use doses in the range of two to four tablets in future fixed-dose controlled studies,” added Dr. Rose.

 “We are highly encouraged by the results of the study.  The rapidity and magnitude of the response to low dose Visicol® in constipated patients compare favorably with the results of studies with the leading prescription laxatives, Miralax® and Zelnorm®,” said Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executuve Officer of InKine.  “We intend to pursue a constipation indication for Visicol®, which if approved, should add significantly to the revenues from this product,” added Dr. Jacob.

 About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol® is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat®, is an oral hyoscyamine spray for the treatment of a variety of indications.  Additionally, the Company has filed a provisional patent application for the development of a new generation purgative, for which clinical trials are expected to initiate during 2004, and is developing Colirest™, which is in clinical trials for the treatment of Crohn's disease. For further information, please visit InKine on its web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.